# Full year trading update

RNS Number : 6401P
Novacyt S.A.
21 January 2026

**Novacyt S.A.**

**("Novacyt", the "Company" or the "Group")**

**Full year trading update**

**Paris, France and Manchester, UK - 21 January 2026 -** Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year trading update for the year ended 31 December 2025 ("FY 2025"), a period where revenues met market expectations, the Group maintained sequential half-year revenue growth and the cash position remained strong.

**Financial highlights (unaudited)**

· Group statutory revenue for FY 2025 is expected to be c. £20.0m (FY 2024: £19.6m), in line with market expectations of £19.8m

· Underlying Group revenue grew by c.4% (5% on a constant currency basis), excluding the impact of the Taiwan service laboratory divestment

· **Clinical** segment delivered sales of £13.8m, (FY 2024: £13.5m), representing growth of 3%, driven by the acquisition of a new strategic customer in the APAC region

- Within this segment NIPT technologies was up over 10% year-on-year

· **Instrumentation** segment delivered more than 25% growth in sales to £2.5m, (FY 2024: £2.0m) predominantly driven by the LightBench® Discover instrument

· **RUO** segment declined year-on-year by c. 10% to £3.7m (FY 2024: £4.2m), as a result of reduced sales of the Primerdesign catalogue of products

· APAC region delivered the highest year-on-year growth of c. 10% achieving sales of £5.5m, driven by the continued strong demand for the Company's Reproductive Health range of products, followed by the Americas region delivering growth of c. 8%

· Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6m in H2 2024 to £10.2m in H2 2025

· EBITDA losses will at least meet, or show an improvement to, market expectations, as a result of careful cost management

· Cash position at 31 December 2025 was £19.2m (30 June 2025: £23.8m), and the Group remains debt free

The Board understands that market expectations for the year ended 31 December 2025 to be revenue of £19.8m, an adjusted EBITDA loss of £8.5m and a closing cash balance of £18.8m.

**Commercial progress**

The Instrumentation segment delivered more than 25% revenue growth in the period, predominately driven by the launch of the LightBench® Discover instrument, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. Since its launch in July 2025, the Company has successfully placed 10 instruments, with multiple collaborations secured and demonstrations to customers delivered. The Group confirms a healthy pipeline of opportunities for 2026 and beyond, as customers proactively reach out to learn more about this technology.

Despite the decline in sales within the Company's RUO segment, the Group successfully launched Primerdesign exsig® Mag RapidBead Pro Extraction Kit in November 2025. The cost-efficient, end-to-end solution, delivers superior performance for the Group's partners, setting a new standard for DNA/RNA purification. Combining the proven reliability of the exsig® Mag kit and the speed of a next-generation rapid extraction workflow, the kit helps researchers accelerate molecular discovery and pathogen testing from sample to results.

Finally, Beta testing is underway with international key opinion leaders in the field of precision medicine for Yourgene's *Insight* DPYD assay, the enhanced DPYD test which helps identify cancer patients at risk of suffering a severe and potentially life-threatening reaction to common chemotherapy. This Beta testing has commenced in good time, ahead of the product launch expected in H1 2026.

**Final results**

The Group expects to report its full year results for the year ended 31 December 2025 during April 2026.

**Commenting on the trading update Lyn Rees, CEO of Novacyt, said:** *"With the period of restructuring and integration completed, and the successful derisked and stabilised business formed, we committed as a Board to deliver top line growth. We're therefore pleased to have delivered year on year revenue growth in line with market expectations. It's also pleasing to report two consecutive periods of half-year growth underpinned by an upward trajectory of revenue growth. These results prove the strong foundation we have created as a Group, and we look forward to driving innovation further as we continue to execute and deliver on our plans."*

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

**Contacts**

| | |
|---|---|
| **Novacyt SA** | https://novacyt.com/investors |
| Lyn Rees, Chief Executive Officer | **Via Walbrook PR** |
| Steve Gibson, Chief Financial Officer | |

| | |
|---|---|
| **SP Angel Corporate Finance LLP (Nominated Adviser and Broker)** | +44 (0)20 3470 0470 |
| Matthew Johnson / Charlie Bouverat (Corporate Finance)<br>Vadim Alexandre / Rob Rees (Corporate Broking) | |

| | |
|---|---|
| **Singer Capital Markets (Joint Broker)** | +44 (0) 20 7496 3000 |
| Phil Davies / James Fischer / Samed Ethemi | |

| | |
|---|---|
| **Allegra Finance (French Listing Sponsor)**<br>Rémi Durgetto / Yannick Petit | +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com |

| | |
|---|---|
| **Walbrook PR (Financial PR & IR)**<br>Paul McManus / Lianne Applegarth<br>Alice Woodings | +44 (0)20 7933 8780 or novacyt@walbrookpr.com<br>+44 (0)7980 541 893 / +44 (0)7584 391 303<br>+44 (0)7407 804 654 |

**About Novacyt Group** (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

| | |
|---|---|
| **Clinical** | Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:<br>· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests<br>· Precision Medicine: DPYD genotyping assay<br>· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel |
| **Instrumentation** | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:<br>· Ranger® Technology: automated DNA sample preparation and target enrichment technology<br>· genesig q16 and q32 real-time quantitative PCR (qPCR) instruments |
| **Research Use Only** | Range of services for the life sciences industry:<br>· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry<br>· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |

Novacyt is headquartered in Le Vésinet in France with offices in the UK (in Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTBSGDBRXDDGLG